Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Prostatic Neoplasms 8Neuroendocrine Tumors 3Esophageal Neoplasms 3Carcinoma, Hepatocellular 3Lymphoma, Non-Hodgkin 2Lymphoma 2Disease 2Brain Neoplasms 2Vulvar Neoplasms 1Vulvar Diseases 1Vasculitis 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Stomach Neoplasms 1Solid Tumor, Adult 1Smoking Cessation 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Papillomavirus Infections 1Pancreatic Neoplasms 1Pancreatic Cystic Neoplasms 1Osteomyelitis 1Nose Neoplasms 1Neurodegenerative Diseases 1Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Multiple Pulmonary Nodules 1

Interventions

Rituximab 187Cyclophosphamide 174Etoposide 94Peripheral Blood Stem Cell Transplantation 90Vincristine 89Prednisone 80Doxorubicin 79Filgrastim 75fludarabine phosphate 60Radiotherapy 56Mycophenolic Acid 41Melphalan 41Cytarabine 41Busulfan 40Cyclosporine 39Methotrexate 37Whole-Body Irradiation 36Tacrolimus 35Carmustine 34Ifosfamide 28Lenalidomide 27Granulocyte Colony-Stimulating Factor 27Antilymphocyte Serum 27Gemcitabine 25Carboplatin 25Methylprednisolone 24ibritumomab tiuxetan 23Bortezomib 22Dexamethasone 21ibrutinib 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoma, Large B-Cell, Diffuse × Positron-Emission Tomography × Clear all
NCT00001337 2025-06-22

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
348 enrolled 15 charts
Lymphoid

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡